-
Published 5/18/2026
Hughes JA, Brooks KM, Fairlie L, Best BM, Mirochnick M, Hesseling AC, Decloedt E, Pinilla M, Shapiro DE, Eke AC. Letter Reply to "Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis". J Infect Dis. 2026 May 18. PMID: 42149552.
-
Published 1/17/2026
Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, Stek A, Best BM, Mirochnick M, Wiesner L, George K, Knowles K, Browning R, DeYampert T, Hesseling AC, Decloedt E, Shapiro DE, Eke AC. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026 Jan 17; 233(1):16-26. PMID: 41165222.
-
Published 1/1/2026
Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134. PMID: 41405169.
-
Published 11/12/2025
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson P, Myer L, Celum C, Heffron R, Coleman J, Davey DJ, Hendrix CW, Momper JD, Bies R, Scott RK. Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. Clin Pharmacokinet. 2026 Jan; 65(1):133-148. PMID: 41222898.
-
Published 5/19/2025
Iannella N, Momper J, Mirochnick M, Suhandynata RT, Saia K, Werler M, Jones HE, Wachman EM. Pharmacokinetics of Oral and Extended-release Naltrexone in Pregnant and Lactating Individuals and their Infants. J Addict Med. 2026 Jan-Feb 01; 20(1):62-69. PMID: 40388713.